Evaluation of the safety of a polyvalent vaccinia virus-HIV-1 envelope recombinant vaccine (PolyEnv1) in healthy adults.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV infections
- Focus Adverse reactions
- 29 Sep 2011 Biomarkers information updated
- 01 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00187044).
- 01 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00187044).